AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31785056 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin (PG) inpatient group (Dinoprostone, either 2 mg gel or 10 mg controlled-release tape)
Number of subjects: 695
Study 31785056 — intervention group
Group type: COMPARATOR
Intervention: Balloon outpatient group (double-balloon catheter inserted and went home)
Number of subjects: 695
Study 31785056 — intervention group
Group type: COMPARATOR
Intervention: Balloon outpatient group
Number of subjects: 695
Study 31785056 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin (PG) inpatient group
Number of subjects: 695
Study 31045422 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAF intervention (N = 86)
Number of subjects: 170
Study 31045422 — intervention group
Group type: COMPARATOR
Intervention: Emotion reporting/waitlist control (N = 84)
Number of subjects: 170
Study 28926528 — intervention group
Group type: EXPERIMENTAL
Intervention: Community symptom awareness campaign tailored for rural Australians
Number of subjects: 1358
Study 28926528 — intervention group
Group type: EXPERIMENTAL
Intervention: GP intervention: resource card with symptom risk assessment charts and local cancer referral pathways
Number of subjects: 1358
Study 28926528 — intervention group
Group type: COMPARATOR
Intervention: Community campaign control region
Number of subjects: 1358
Study 28926528 — intervention group
Group type: COMPARATOR
Intervention: GP control
Number of subjects: 1358
Study 27230616 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made serially adjustable rigid wrist/hand orthoses (WHO), prescribed for 6 hours nightly (or daily) for 3 years.
Number of subjects: 194
Study 27230616 — intervention group
Group type: COMPARATOR
Intervention: Usual multidisciplinary care (control group).
Number of subjects: 194
Study 24387929 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder neck sling suspension technique
Number of subjects: 57
Study 22588639 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS applied to the contralesional M1 for 30 minutes before motor training
Number of subjects: 40
Study 22588639 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS for 30 minutes before motor training
Number of subjects: 40
Study 20402874 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 1.5 mg.kg(‐1) (Group S)
Number of subjects: 60
Study 20402874 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 1 mg.kg(‐1) (Group R)
Number of subjects: 60
Study 20402874 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 1.5 mg.kg(‐1) (Group SO)
Number of subjects: 60
Study 17379588 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocytapheresis
Number of subjects: 40
Study 17379588 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 40
Study 15668474 — intervention group
Group type: EXPERIMENTAL
Intervention: Oophorectomy and tamoxifen treatment for breast cancer
Number of subjects: 682
Study 15668474 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 682
Study 15668474 — intervention group
Group type: COMPARATOR
Intervention: Parity and age at first birth
Number of subjects: 682
Study 15668474 — intervention group
Group type: COMPARATOR
Intervention: Family history, age at menarche, cumulative lactation, body mass index, education
Number of subjects: 682
Study 12042545 — intervention group
Group type: EXPERIMENTAL
Intervention: Community nurse (home visit) follow-up
Number of subjects: 586
Study 12042545 — intervention group
Group type: COMPARATOR
Intervention: Hospital nurse (clinic) follow-up
Number of subjects: 586
Study 9709910 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS-A pattern (intraparenchymal homogeneous vascular color spots)
Number of subjects: 16
Study 9709910 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS-B pattern (vascular bands with avascular areas)
Number of subjects: 16
Study 9709910 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed pattern (A-B pattern)
Number of subjects: 16
Study 9709910 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal TRAb levels
Number of subjects: 16
Study 9709910 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS patterns
Number of subjects: 16
Study 9709910 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological findings
Number of subjects: 16
Study 9709910 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity of systolic peak (VP)
Number of subjects: 16
Study 7874900 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound measurements after blood donation
Number of subjects: 7
Study 7874900 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements before hemorrhage
Number of subjects: 7
Study 7874900 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements 24 hours after hemorrhage
Number of subjects: 7
Study 2147043 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacron graft with collagen coating
Number of subjects: 128
Study 2147043 — intervention group
Group type: COMPARATOR
Intervention: Dacron graft (non-collagen coated)
Number of subjects: 128
Study 152180 — intervention group
Group type: EXPERIMENTAL
Intervention: Iocetamic acid (Cholebrin)
Number of subjects: 50
Study 152180 — intervention group
Group type: COMPARATOR
Intervention: Calcium ipodate (Solubiloptin)
Number of subjects: 50
Study 152180 — intervention group
Group type: COMPARATOR
Intervention: Both contrast media
Number of subjects: 50
Study 31624988 — intervention group
Group type: EXPERIMENTAL
Intervention: Symfony ZXR00
Number of subjects: 115
Study 31624988 — intervention group
Group type: EXPERIMENTAL
Intervention: ZLB00
Number of subjects: 115
Study 31624988 — intervention group
Group type: EXPERIMENTAL
Intervention: SV25T0
Number of subjects: 115
Study 31624988 — intervention group
Group type: EXPERIMENTAL
Intervention: ATLISA 809M, ATLISA Tri 839MP, ZLB00
Number of subjects: 115
Study 30187221 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition supplements
Number of subjects: 20
Study 30187221 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard polymeric supplements
Number of subjects: 20
Study 30187221 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition supplements (both types)
Number of subjects: 20
Study 30256102 — intervention group
Group type: EXPERIMENTAL
Intervention: Single water treatment interventions
Number of subjects: 0
Study 30256102 — intervention group
Group type: EXPERIMENTAL
Intervention: Single water treatment and handwashing interventions
Number of subjects: 0
Study 30256102 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined WSH interventions
Number of subjects: 0
Study 30256102 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions (WSH improvements)
Number of subjects: 0
Study 30256102 — intervention group
Group type: EXPERIMENTAL
Intervention: Water treatment and handwashing
Number of subjects: 0
Study 30256102 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interventions
Number of subjects: 0
Study 27610423 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus iChoose Kidney
Number of subjects: 450
Study 27610423 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (usual transplantation education)
Number of subjects: 450
Study 24192062 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of leukotriene receptor antagonist (LRA), H1 antihistamine, and H2 antihistamine (Group A)
Number of subjects: 50
Study 24192062 — intervention group
Group type: COMPARATOR
Intervention: Control group continued with previously taken two combination regimens (Group B)
Number of subjects: 50
Study 22648629 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium fibre added to extruded snack products
Number of subjects: 0
Study 22648629 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran inclusion in extruded snack products
Number of subjects: 0
Study 22648629 — intervention group
Group type: COMPARATOR
Intervention: Control snack product recipe
Number of subjects: 0
Study 19156564 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration
Number of subjects: 0
Study 19156564 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral cue words
Number of subjects: 0
Study 19156564 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative cue words
Number of subjects: 0
Study 19156564 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical arousal during memory retrieval
Number of subjects: 0
Study 19156564 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17618330 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic metronidazole and amoxicillin (500 mg amoxicillin + 250 mg metronidazole every eight hours for seven days) with scaling and root planing
Number of subjects: 50
Study 17618330 — intervention group
Group type: COMPARATOR
Intervention: Placebo with scaling and root planing
Number of subjects: 50
Study 17618330 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic metronidazole and amoxicillin with scaling and root planing
Number of subjects: 50
Study 15274152 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fibrinolysis with 50 mg of alteplase and abciximab (n = 34)
Number of subjects: 70
Study 15274152 — intervention group
Group type: COMPARATOR
Intervention: Primary angioplasty with adjunctive abciximab (n = 36)
Number of subjects: 70
Study 11260099 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop Transverse Colostomy (LTC)
Number of subjects: 70
Study 11260099 — intervention group
Group type: COMPARATOR
Intervention: Loop Ileostomy (LI)
Number of subjects: 70
Study 9704725 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg mitomycin bound to a solution of 375 mg carbo adsorbens intraperitoneally before closure of the abdominal wound (n = 46)
Number of subjects: 91
Study 9704725 — intervention group
Group type: COMPARATOR
Intervention: Surgical control group (n = 45)
Number of subjects: 91
Study 9704725 — intervention group
Group type: EXPERIMENTAL
Intervention: M-CH therapy
Number of subjects: 91
Study 8208399 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum concentration of 4-aminopyridine (30 to 59 ng/ml)
Number of subjects: 8
Study 8208399 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum concentration of 4-aminopyridine (60 to 100 ng/ml)
Number of subjects: 8
Study 8208399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2536599 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) administered at 15 ng/kg/min for hour 1 and 50 ng/kg/min for hour 2, preceded by a 50-micrograms bolus
Number of subjects: 8
Study 2536599 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 8
Study 2536599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31630600 — intervention group
Group type: EXPERIMENTAL
Intervention: Alalfy modified cervical inversion technique plus hemostatic sutures
Number of subjects: 240
Study 31630600 — intervention group
Group type: COMPARATOR
Intervention: Control group (hemostatic sutures only)
Number of subjects: 240
Study 31915178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast breathing pneumonia recurrence
Number of subjects: 4003
Study 31915178 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor-quality housing (katcha or mixed type)
Number of subjects: 4003
Study 31915178 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental predictors (housing type, indoor air quality, etc.)
Number of subjects: 4003
Study 31197095 — intervention group
Group type: EXPERIMENTAL
Intervention: High cadence cycling (3 sessions on a custom motorized stationary ergometer)
Number of subjects: 35
Study 31197095 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 35
Study 29059017 — intervention group
Group type: EXPERIMENTAL
Intervention: Health information technology (HIT) diabetes self‐management education (DSME) intervention, including a 1-time training session lasting 73.6 minutes and additional on-site sessions based on need.
Number of subjects: 220
Study 29059017 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic technology help and introduction to the Mobile Diabetes Detective (MoDD) website and text message features.
Number of subjects: 220
Study 29059017 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site visits for usual care were collected as part of the intervention.
Number of subjects: 220
Study 25491276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular platelet-rich plasma (PRP) injection
Number of subjects: 20
Study 25491276 — intervention group
Group type: COMPARATOR
Intervention: Arthrocentesis
Number of subjects: 20
Study 24317850 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitumor treatment
Number of subjects: 196
Study 24317850 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher spiritual well‐being scores
Number of subjects: 196
Study 24317850 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher spiritual well‐being
Number of subjects: 196
Study 24317850 — intervention group
Group type: EXPERIMENTAL
Intervention: Religiousness
Number of subjects: 196
Study 24317850 — intervention group
Group type: COMPARATOR
Intervention: Race
Number of subjects: 196
Study 22491380 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing frequency
Number of subjects: 237
Study 22491380 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status
Number of subjects: 237
Study 22491380 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 237
Study 22491380 — intervention group
Group type: EXPERIMENTAL
Intervention: External locus of control
Number of subjects: 237
Study 22491380 — intervention group
Group type: EXPERIMENTAL
Intervention: IQPI
Number of subjects: 237
Study 22491380 — intervention group
Group type: EXPERIMENTAL
Intervention: IQPI and gender
Number of subjects: 237
Study 19469186 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapeutic approaches targeting TRPV1 receptors, cytokine receptors, neuropeptide receptors, glutamate receptors, sodium and calcium channels.
Number of subjects: 0
Study 19469186 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of neuronal mechanisms of placebo effects.
Number of subjects: 0
Study 17767819 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical respiratory frequency set at 5, 10, 15, and 20 breaths per minute
Number of subjects: 12
Study 15881485 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day (RLX)
Number of subjects: 5133
Study 15881485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5133
Study 12450717 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond FL (OB) with immediate placement (IP)
Number of subjects: 8
Study 12450717 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (PB) with immediate placement (IP)
Number of subjects: 8
Study 12450717 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond FL (OB) with delayed placement (DP)
Number of subjects: 8
Study 12450717 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (PB) with delayed placement (DP)
Number of subjects: 8
Study 12450717 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 8
Study 10510990 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol, 100 mg, twice a day
Number of subjects: 516
Study 10510990 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol, 50 mg, twice a day
Number of subjects: 516
Study 10510990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study 7862386 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin sodium (100 U/mL)
Number of subjects: 64
Study 7862386 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (0.9% sodium chloride)
Number of subjects: 64
Study 2018339 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 33 micrograms/hr fentanyl for 48 hours in group X
Number of subjects: 27
Study 2018339 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with 33 micrograms/hr fentanyl for 48 hours in group Y
Number of subjects: 27
Study 7056864 — intervention group
Group type: EXPERIMENTAL
Intervention: Fake good instruction
Number of subjects: 240
Study 7056864 — intervention group
Group type: EXPERIMENTAL
Intervention: Fake bad instruction
Number of subjects: 240
Study 7056864 — intervention group
Group type: EXPERIMENTAL
Intervention: Fake average instruction
Number of subjects: 240
Study 7056864 — intervention group
Group type: COMPARATOR
Intervention: Actual feelings (trial 1)
Number of subjects: 240
Study 30758289 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based supportive educational parenting program (SEPP)
Number of subjects: 236
Study 30758289 — intervention group
Group type: COMPARATOR
Intervention: Routine perinatal care (Control)
Number of subjects: 236
Study 27896921 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (27 mg of iron)
Number of subjects: 114
Study 27896921 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (Fe-B group)
Number of subjects: 114
Study 27896921 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron groups combined
Number of subjects: 114
Study 27896921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 27896921 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron groups (among women without elevated CRP)
Number of subjects: 114
Study 27896921 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron groups
Number of subjects: 114
Study 26498958 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic acromioplasty (AA) alone
Number of subjects: 60
Study 26498958 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic acromioplasty (AA) with autologous PRP injection (AA + PRP)
Number of subjects: 60
Study 23485610 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release carbidopa-levodopa
Number of subjects: 471
Study 23485610 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release carbidopa-levodopa
Number of subjects: 471
Study 21464888 — intervention group
Group type: EXPERIMENTAL
Intervention: Probation Case Management (PCM)
Number of subjects: 183
Study 21464888 — intervention group
Group type: COMPARATOR
Intervention: Standard Probation
Number of subjects: 183
Study 19289487 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) performance time
Number of subjects: 57
Study 19289487 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) functional ability scale (FAS)
Number of subjects: 57
Study 17317877 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline intravenous
Number of subjects: 8
Study 17317877 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45% saline intravenous
Number of subjects: 8
Study 17317877 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45% saline oral
Number of subjects: 8
Study 17317877 — intervention group
Group type: COMPARATOR
Intervention: No Rehy (no fluid)
Number of subjects: 8
Study 15548244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release morphine sulfate (SRMS) 30 mg
Number of subjects: 51
Study 15548244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11496941 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin (OXY) administered via a single transdermal system over a 96 h wear period
Number of subjects: 18
Study 11496941 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxybutynin (OXY) administered as a single 5 mg immediate-release tablet
Number of subjects: 18
Study 9603587 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapneic group
Number of subjects: 19
Study 9603587 — intervention group
Group type: COMPARATOR
Intervention: Eucapneic group
Number of subjects: 19
Study 8172137 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MU of L-IFN
Number of subjects: 30
Study 8172137 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU of L-IFN
Number of subjects: 30
Study 8172137 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 8172137 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU of L-IFN (24 weeks after stopping treatment)
Number of subjects: 30
Study 8172137 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MU of L-IFN (24 weeks after stopping treatment)
Number of subjects: 30
Study 8172137 — intervention group
Group type: COMPARATOR
Intervention: Control group (24 weeks after stopping treatment)
Number of subjects: 30
Study 8172137 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (2',5'-Oligoadenylate synthetase activities)
Number of subjects: 30
Study 8172137 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU of L-IFN (anti-HCV titers)
Number of subjects: 30
Study 3293631 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 551
Study 3293631 — intervention group
Group type: COMPARATOR
Intervention: Placebos
Number of subjects: 551
Study 30454042 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous landiolol infusion to reach a target HR of 80-94 bpm along with standard treatment according to the Surviving Sepsis Campaign Guidelines 2016
Number of subjects: 200
Study 30454042 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 200
Study 28027332 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/d opicapone
Number of subjects: 427
Study 28027332 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/d opicapone
Number of subjects: 427
Study 28027332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 26122504 — intervention group
Group type: EXPERIMENTAL
Intervention: MON-400BUD (low-dose inhaled budesonide + montelukast)
Number of subjects: 128
Study 26122504 — intervention group
Group type: COMPARATOR
Intervention: 800BUD (medium-dose inhaled budesonide)
Number of subjects: 128
Study 26122504 — intervention group
Group type: EXPERIMENTAL
Intervention: MON-400BUD
Number of subjects: 128
Study 26122504 — intervention group
Group type: COMPARATOR
Intervention: 800BUD
Number of subjects: 128
Study 23316693 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic hyperglycaemic clamp (50 m-units·m⁻²·min⁻¹, 10 mmol/l)
Number of subjects: 7
Study 23316693 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemic euinsulinaemic clamp (10 mmol/l, 5 m-units·m⁻²·min⁻¹)
Number of subjects: 7
Study 23316693 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic euglycaemic clamp (50 m-units·m⁻²·min⁻¹, 4.5 mmol/l)
Number of subjects: 7
Study 21464451 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 18